薬物動態
Print ISSN : 0916-1139
ゲノム創薬と遺伝子治療をめざしたリボザイム技術の開発
川崎 広明
著者情報
ジャーナル フリー

2001 年 16 巻 supplement 号 p. 130-131

詳細
抄録
We constructed a novel RNA-protein hybrid ribozyme that have the site-specific cleavage activity of the hammerhead ribozyme and the unwinding activity of the endogenous RNA helicase. This hybrid ribozyme leads to extremely efficient cleavage of any target mRNA regardless of the secondary structure of the RNA. Since the novel hybrid ribozymes can attack any site within mRNA, libraries were made of the hybrid ribozymes with randomized binding arms and introduced into cells. This procedure made it possible to readily identify the relevant genes associated with phenotype in the apoptosis pathway. This application of a randomized library of hybrid ribozymes represents a simple powerful method for identification of genes associated with specific phenotypes in the post genome era.
著者関連情報
© 日本薬物動態学会
前の記事 次の記事
feedback
Top